Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7515629 in Participants With Unresectable and/or Metastatic HLA-G Positive Solid Tumors

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).

Study Overview

• Status: Not yet recruiting
• Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
• Intervention / Treatment: Drug: RO7515629; Drug: tocilizumab

• Study Type: Interventional
• Enrollment (Anticipated): 150
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Reference Study ID Number: BP44068 https://forpatients.roche.com/; Phone Number: 888-662-6728 (U.S. and Canada); Email: [email protected]

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Unresectable and/or metastatic HLA-G-positive solid tumors, for which standard therapy does not exist, or has proven to be ineffective or intolerable

• The following tumor histologies will be permitted:

  • Part 1: renal cell carcinoma (clear cell, papillary or chromophobe subtypes), non-small cell lung cancer (squamous or non-squamous), pancreatic adenocarcinoma
  • Part 2: renal cell carcinoma (clear cell, papillary or chromophobe subtypes), non-small cell lung cancer (squamous or non-squamous), pancreatic adenocarcinoma, colorectal cancer
  • Part 3: renal cell carcinoma with a clear-cell component; must have IMDC poor or intermediate risk disease and must have received no more than 3 prior systemic therapies in the advanced or metastatic setting (prior treatment must include an immune checkpoint inhibitor)
• Confirmed HLA-G tumor expression. Participants without archival tumor tissue available for testing must have a lesion amenable to biopsy.
• Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Life expectancy of at least 12 weeks
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate hematological, liver, renal and pulmonary function
• Willingness to abide by protocol defined contraceptive requirements for the duration of the study.

Exclusion Criteria:

• History or clinical evidence of Central Nervous System (CNS) metastases unless protocol specified criteria are met
• Leptomeningeal metastases
• Rapid disease progression including lesions that are a threat to vital organs or non-irradiated lesions 2cm or larger at critical sites where tumor swelling may pose a risk to critical anatomical structures
• Participants with another invasive malignancy in the last 2 years unless protocol specified criteria are met
• Uncontrolled hypertension
• Active interstitial lung disease (ILD), pneumonitis or a history of ILD/pneumonitis requiring treatment with steroids, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest Computed Tomography (CT) scan
• Participants with >10 bilateral pulmonary lesions (i.e., at least one lesion in each lung and more than 10 lung lesions in total) or pulmonary miliary metastatic pattern or pulmonary lymphangitic carcinomatosis
• Significant cardiovascular disease
• Presence of active or uncontrolled infection or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to initiation of study treatment.
• Known hepatitis B or C (actively replicating) based on protocol specified criteria
• Known Human Immunodeficiency Virus (HIV) positivity
• Presence of an indwelling line or drain
• Active auto-immune disease that has required systemic therapy within the past 2 years unless protocol specified exceptions are met
• Major surgery within 28 days prior to first study treatment
• Last treatment with anti-cancer therapy or any investigational drug 28 days or less prior to the first study treatment
• Last dose of immunostimulating or immunosuppressive therapy 28 days or less prior to the first study treatment
• Regular dose of corticosteroids that exceeds prednisone 10 mg/day or equivalent within 28 days prior to first study treatment
• Prior treatment with T cell engaging or adoptive cell therapy
• Administration of a live, attenuated vaccine 28 days or less prior to first study treatment
• Contraindication or known hypersensitivity to any of the components of RO7515629 or tocilizumab or dexamethasone

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part I Single Participant Cohort RO7515629 Dose Escalation; Participants will receive a fixed dose of RO7515629 intravenously as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.	Drug: RO7515629; RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.; Drug: tocilizumab; Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).; Other Names: Actemra, RoActemra
Experimental: Part II Multiple Participant Cohort RO7515629 Dose Escalation; Participants will receive RO7515629 intravenously, as a single agent on cycle 0 day -7 and 7 days later on cycle 1 day 1 followed by every three-week dosing frequency. In case of toxicity, step up dosing (single or double) may be implemented. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.	Drug: RO7515629; RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.; Drug: tocilizumab; Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).; Other Names: Actemra, RoActemra
Experimental: Part III Multiple Participant Cohort RO7515629 Dose Expansion; Participants with selected solid tumors will receive a selected dose of RO7515629 intravenously as a single agent based on the recommended dose sequence for expansion (RDE) and dosing regimen selected from Part I and Part II. Treatment may continue for up to 12 months maximum or until progression, loss of clinical benefit, intolerable toxicity, withdrawal from study treatment or death.	Drug: RO7515629; RO7515629 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.; Drug: tocilizumab; Tocilizumab will be used as rescue medication only. Tocilizumab will be administered as required for the management of cytokine release syndrome (CRS).; Other Names: Actemra, RoActemra

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Part 1, 2, 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Up to 15 months
Part 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)	From start of study treatment (cycle 0 day -7 or cycle 0 day -14) until two weeks after second or third RO7515629 infusion (cycle 1 day 1) for a total DLT window of up to 28 days.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1, 2, 3: Pharmacokinetic Analysis: Maximum Serum Concentration (Cmax) of RO7515629		Up to 13 months
Part 1, 2, 3: Pharmacokinetic Analysis: Time of Maximum Serum Concentration (Tmax) of RO7515629		Up to 13 months
Part 1, 2, 3: Pharmacokinetic Analysis: Minimum Serum Concentration (Cmin) of RO7515629		Up to 13 months
Parts 1, 2, 3: Pharmacokinetic Analysis: Clearance (CL) of RO7515629		Up to 13 months
Part 1, 2, 3: Pharmacokinetic Analysis: Volume of Distribution at Steady State (Vss) of RO7515629		Up to 13 months
Part 1, 2, 3: Pharmacokinetic Analysis: Area Under The Curve (AUC) of RO7515629		Up to 13 months
Part 1, 2, 3: Number of Participants With RO7515629 Anti-drug Antibodies (ADAs)		Up to 13 months
Part 1, 2, 3: Objective Response Rate (ORR)		Up to approximately 18 months
Part 1, 2, 3: Disease Control Rate (DCR)		Up to approximately 18 months
Part 1, 2, 3: Duration of Response (DoR)		Up to approximately 18 months
Part 1, 2, 3: Progression Free Survival (PFS)		Up to approximately 18 months
Part 1, 2, 3: Overall survival (OS)	Defined as the time from first dose of study treatment to time of death.	Up to approximately 18 months

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Investigators: Study Director: Clinical Trials, Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start (Anticipated): April 25, 2023
• Primary Completion (Anticipated): January 29, 2027
• Study Completion (Anticipated): January 29, 2027

Study Registration Dates

• First Submitted: March 3, 2023
• First Submitted That Met QC Criteria: March 3, 2023
• First Posted (Actual): March 15, 2023

Study Record Updates

• Last Update Posted (Actual): March 15, 2023
• Last Update Submitted That Met QC Criteria: March 3, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Keywords: HLA-G, Human leukocyte antigen G, Renal cell carcinoma, Non-small cell lung cancer, Pancreatic adenocarcinoma, Colorectal cancer, RO7515629, Tocilizumab
• Additional Relevant MeSH Terms: Digestive System Diseases; Respiratory Tract Diseases; Neoplasms by Histologic Type; Neoplasms; Lung Diseases; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Carcinoma; Neoplasms, Glandular and Epithelial; Endocrine System Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Endocrine Gland Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Kidney Neoplasms; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Lung Neoplasms; Pancreatic Diseases; Carcinoma, Renal Cell; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Adenocarcinoma; Pancreatic Neoplasms
• Other Study ID Numbers: BP44068

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No